Individual isotoxic radiation dose escalation based on V20 and advanced technologies benefits unresectable stage III non-small cell lung cancer patients treated with concurrent chemoradiotherapy: long term follow-up.

导出 OA

翻译打印收藏纠错

作者： Ming,Liu ^[1] ; Zhongtang,Wang ^[2] ; Tao,Zhou ^[2] ; Antang,Zhou ^[2] ; Qian,Zhao ^[3] ; Hongsheng,Li ^[2] ; Hongfu,Sun ^[2] ; Wei,Huang ^[2] ; BaoSheng,Li ^[2]

作者单位： School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, Shandong, P.R. China. ^[1] Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong, P.R. China. ^[2] Department of General Surgery, Yanggu People's Hospital, Liaocheng, Shandong, P.R. China. ^[3] Engineering Research Center for Medical Imaging and Radiation Therapy of Shandong Province, Jinan, Shandong, P.R. China. ^[4]

关键词 Individual isotoxic dose escalation advanced radiotherapy technologies chemoradiotherapy lung V20 non-small cell lung cancer

DOI 10.18632/oncotarget.16288

PMID 28881694

发布时间 2018-11-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交